Approaches to Potentiated Neuroprotective Treatment in the Rodent Model of Ischemic Optic Neuropathy.
Animals
Benzodioxoles
/ pharmacology
Disease Models, Animal
Male
Meloxicam
/ pharmacology
Neuroprotective Agents
/ pharmacology
Optic Neuropathy, Ischemic
/ drug therapy
Piperidines
/ pharmacology
Prostaglandin Antagonists
/ pharmacology
Rats
Rats, Sprague-Dawley
Retinal Ganglion Cells
/ drug effects
PGJ2
animal model
gene expression
inflammation
ischemia
neuroprotection
nonarteritic anterior ischemic optic neuropathy (NAION)
optic nerve
prostaglandin
retinal ganglion cell
rodent
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
09 06 2021
09 06 2021
Historique:
received:
25
04
2021
revised:
31
05
2021
accepted:
03
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Nonarteritic anterior ischemic optic neuropathy (NAION) commonly causes sudden optic nerve (ON)-related vision loss. The rodent NAION model (rAION) closely resembles NAION in presentation and physiological responses. We identified early rAION-associated optic nerve head (ONH) inflammatory gene expression responses and the anti-inflammatory prostaglandin PGJ
Identifiants
pubmed: 34207618
pii: cells10061440
doi: 10.3390/cells10061440
pmc: PMC8228425
pii:
doi:
Substances chimiques
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(benzo(d)(1,3)dioxol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate
0
Benzodioxoles
0
Neuroprotective Agents
0
Piperidines
0
Prostaglandin Antagonists
0
Meloxicam
VG2QF83CGL
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NEI NIH HHS
ID : R01 EY015304
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY010343
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY028690
Pays : United States
Organisme : Hillside Foundation
ID : 2015-01
Références
Cell Rep. 2012 Jun 28;1(6):617-23
pubmed: 22813736
Stroke. 2018 Mar;49(3):718-726
pubmed: 29440474
Angiogenesis. 2018 May;21(2):395-413
pubmed: 29445990
Science. 2011 Nov 11;334(6057):809-13
pubmed: 22021672
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4153-62
pubmed: 14507856
Chem Biol. 2012 May 25;19(5):579-88
pubmed: 22542104
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19045-50
pubmed: 16365293
Invest Ophthalmol Vis Sci. 2014 Oct 08;55(11):7047-56
pubmed: 25298416
PLoS One. 2014 Nov 26;9(11):e113689
pubmed: 25426930
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4844-9
pubmed: 10781090
Graefes Arch Clin Exp Ophthalmol. 2018 May;256(5):935-949
pubmed: 29504043
Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7679-86
pubmed: 26624498
Ophthalmology. 2003 Oct;110(10):2031-5
pubmed: 14522783
Exp Eye Res. 2005 Dec;81(6):700-9
pubmed: 15967434
Brain Res. 2009 Apr 6;1264:67-75
pubmed: 19401181
J Neuroinflammation. 2017 Jan 5;14(1):3
pubmed: 28086956
J Clin Neurosci. 2009 Aug;16(8):994-1000
pubmed: 19596112
Pharmacol Ther. 2011 May;130(2):191-201
pubmed: 21295073
Chem Biol. 2007 Dec;14(12):1347-56
pubmed: 18096503
Nat Med. 2006 Feb;12(2):225-9
pubmed: 16432513
J Neuroimmunol. 2007 Mar;184(1-2):172-9
pubmed: 17275922
Br J Pharmacol. 2014 Mar;171(6):1392-407
pubmed: 23848221
J Neuroophthalmol. 2003 Jun;23(2):157-63
pubmed: 12782932
Clin Biochem. 2018 Sep;59:17-24
pubmed: 30003880
Neuropharmacology. 2015 Apr;91:148-56
pubmed: 25497453
Curr Eye Res. 2008 Apr;33(4):365-76
pubmed: 18398711
Exp Neurol. 2003 Dec;184(2):746-52
pubmed: 14769366
Eye (Lond). 2015 Jan;29(1):65-79
pubmed: 24993324
Mol Neurobiol. 2016 Sep;53(7):4754-71
pubmed: 26328537
Invest Ophthalmol Vis Sci. 2013 Nov 11;54(12):7402-9
pubmed: 24106118
PLoS One. 2012;7(12):e50021
pubmed: 23284631
J Neuroimmunol. 2009 Mar 31;208(1-2):87-93
pubmed: 19203800
Br J Pharmacol. 2017 Dec;174(23):4523-4539
pubmed: 28963716